If at First Tirzepatide Doesn’t Succeed, Keep Trying
NEW ORLEANS — When using tirzepatide (Zepbound, Eli Lilly) to treat obesity, patience may pay off. New post hoc data from Lilly’s SURMOUNT-1 trial of people with overweight or obesity but not diabetes suggest that the drug will almost always produce at least 5% weight loss eventually, even among slow responders. “Some obesity treatment guidelines…